Viking Therapeutics (VKTX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

VKTX Stock Forecast

Viking Therapeutics stock forecast is as follows: an average price target of $97.80 (represents a 135.72% upside from VKTX’s last price of $41.49) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

VKTX Price Target

The average price target for Viking Therapeutics (VKTX) is $97.80 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $110.00 to $74.00. This represents a potential 135.72% upside from VKTX's last price of $41.49.

VKTX Analyst Ratings

Buy

According to 11 Wall Street analysts, Viking Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VKTX stock is 1 'Strong Buy' (9.09%), 10 'Buy' (90.91%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Viking Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 02, 2024	Biren Amin	Piper Sandler	$74.00	$52.94	39.78%	78.36%
Nov 04, 2024	Yale Jen	Laidlaw	$110.00	$63.14	74.22%	165.12%
Nov 04, 2024	Roger Song	Jefferies	$110.00	$63.14	74.22%	165.12%
Jun 27, 2024	Michael Ulz	Morgan Stanley	$105.00	$47.39	121.57%	153.07%
Jun 25, 2024	Joseph Pantginis	H.C. Wainwright	$90.00	$52.12	72.68%	116.92%
May 16, 2024	Steve Seedhouse	Raymond James	$116.00	$69.06	67.97%	179.59%
May 16, 2024	Joon Lee	Truist Financial	$120.00	$69.53	72.60%	189.23%
Mar 26, 2024	Jay Olson	Oppenheimer	$138.00	$80.83	70.73%	232.61%
Mar 26, 2024	Justin Zelin	BTIG	$125.00	$83.98	48.84%	201.28%
Mar 26, 2024	Samimy Annabel	Stifel Nicolaus	$95.00	$83.87	13.27%	128.97%
Mar 15, 2024	Justin Zelin	BTIG	$100.00	$62.56	59.85%	141.02%
Dec 24, 2022	Maxim Maxim	Maxim Group	$15.00	$8.45	77.51%	-63.85%
Dec 19, 2022	Justin Zelin	BTIG	$20.00	$6.72	197.57%	-51.80%
Dec 19, 2022	Joseph Pantginis	H.C. Wainwright	$21.00	$6.37	229.93%	-49.39%

The latest Viking Therapeutics stock forecast, released on Dec 02, 2024 by Biren Amin from Piper Sandler, set a price target of $74.00, which represents a 39.78% increase from the stock price at the time of the forecast ($52.94), and a 78.36% increase from VKTX last price ($41.49).

Viking Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	3	11
Avg Price Target	$74.00	$98.00	$107.55
Last Closing Price	$41.49	$41.49	$41.49
Upside/Downside	78.36%	136.20%	159.22%

In the current month, the average price target of Viking Therapeutics stock is $74.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 78.36% increase as opposed to Viking Therapeutics's last price of $41.49. This month's average price target is down -24.49% compared to last quarter, and down -31.19% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 02, 2024	Piper Sandler		Overweight	Initialise
Nov 04, 2024	Laidlaw	Buy	Buy	Hold
Nov 04, 2024	Jefferies	Buy	Buy	Hold
Oct 17, 2024	Oppenheimer	Outperform	Outperform	Hold
Sep 25, 2024	Oppenheimer	Outperform	Outperform	Hold
Sep 12, 2024	Morgan Stanley	Overweight	Overweight	Hold
Sep 11, 2024	William Blair	Outperform	Outperform	Hold
Jul 25, 2024	Raymond James	Strong Buy	Strong Buy	Hold
Jul 05, 2024	BTIG	Buy	Buy	Hold
Jun 27, 2024	Morgan Stanley		Overweight	Initialise
Jun 25, 2024	H.C. Wainwright	Buy	Buy	Hold
May 16, 2024	Raymond James		Strong Buy	Upgrade
Mar 26, 2024	Oppenheimer	Outperform	Outperform	Hold
Mar 26, 2024	BTIG	Buy	Buy	Hold
Mar 29, 2023	BTIG	Buy	Buy	Hold
Dec 20, 2022	Maxim Group	Buy	Buy	Hold
Apr 28, 2022	SVB Leerink	Outperform	Outperform	Hold

Viking Therapeutics's last stock rating was published by Piper Sandler on Dec 02, 2024. The company Initialise its VKTX rating from "null" to "Overweight".

Viking Therapeutics Financial Forecast

Viking Therapeutics Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 18	Mar 17	Mar 16	Jun 15
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.64M	$1.06B	$1.67B	$185.40M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.17M	$1.28B	$2.00B	$222.48M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.11M	$851.78M	$1.33B	$148.32M
# Analysts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	8	11	18
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Viking Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VKTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Viking Therapeutics EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 18	Mar 17	Mar 16	Jun 15
# Analysts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	8	11	18
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.29M	$-4.79M	$-3.17M	$-7.59M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-4.39M	$-3.10M	$-3.70M	$-42.59M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.51M	$-2.48M	$-2.96M	$-34.07M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-5.27M	$-3.72M	$-4.44M	$-51.11M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.75%	1.55%	0.86%	0.18%

undefined analysts predict VKTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Viking Therapeutics's previous annual EBITDA (undefined) of $NaN.

Viking Therapeutics Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 18	Mar 17	Mar 16	Jun 15
# Analysts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	8	11	18
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-3.55M	$-5.22M	$-3.59M	$-7.87M
Avg Forecast	$-53.77M	$-52.72M	$-46.79M	$-39.11M	$-56.43M	$-49.94M	$-43.57M	$-40.40M	$-45.79M	$-41.42M	$-36.22M	$-32.55M	$-30.59M	$-26.94M	$-28.99M	$-4.73M	$-3.38M	$-4.18M	$-44.10M
High Forecast	$-53.77M	$-52.72M	$-46.79M	$-39.11M	$-56.43M	$-49.94M	$-43.57M	$-40.40M	$-45.79M	$-41.42M	$-36.22M	$-27.90M	$-24.92M	$-26.94M	$-28.99M	$-3.79M	$-2.70M	$-3.35M	$-35.28M
Low Forecast	$-53.77M	$-52.72M	$-46.79M	$-39.11M	$-56.43M	$-49.94M	$-43.57M	$-40.40M	$-45.79M	$-41.42M	$-36.22M	$-33.71M	$-37.38M	$-26.94M	$-28.99M	$-5.68M	$-4.05M	$-5.02M	$-52.93M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.75%	1.55%	0.86%	0.18%

Viking Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VKTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Viking Therapeutics SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 18	Mar 17	Mar 16	Jun 15
# Analysts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	8	11	18
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.76M	$1.44M	$1.39M	$1.53M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.35M	$932.10K	$1.62M	$8.56M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.82M	$1.12M	$1.95M	$10.27M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.88M	$745.68K	$1.30M	$6.85M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.75%	1.55%	0.86%	0.18%

Viking Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to VKTX last annual SG&A of $1.76M (Mar 18).

Viking Therapeutics EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 18	Mar 17	Mar 16	Jun 15
# Analysts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	8	11	18
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.08	$-0.23	$-0.40	$-1.07
Avg Forecast	$-0.48	$-0.48	$-0.42	$-0.35	$-0.51	$-0.45	$-0.39	$-0.36	$-0.41	$-0.37	$-0.33	$-0.29	$-0.28	$-0.24	$-0.26	$-0.16	$-0.11	$-0.56	$-0.73
High Forecast	$-0.48	$-0.48	$-0.42	$-0.35	$-0.51	$-0.45	$-0.39	$-0.36	$-0.41	$-0.37	$-0.33	$-0.25	$-0.22	$-0.24	$-0.26	$-0.13	$-0.09	$-0.45	$-0.58
Low Forecast	$-0.48	$-0.48	$-0.42	$-0.35	$-0.51	$-0.45	$-0.39	$-0.36	$-0.41	$-0.37	$-0.33	$-0.30	$-0.34	$-0.24	$-0.26	$-0.19	$-0.13	$-0.67	$-0.87
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.50%	2.09%	0.71%	1.47%

According to undefined Wall Street analysts, Viking Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VKTX previous annual EPS of $NaN (undefined).

Viking Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.52	$70.00	13361.54%	Buy
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
VKTX	Viking Therapeutics	$46.70	$97.80	109.42%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
SRPT	Sarepta Therapeutics	$125.76	$187.20	48.85%	Buy
AXSM	Axsome Therapeutics	$93.51	$133.00	42.23%	Buy
MCRB	Seres Therapeutics	$0.88	$1.25	42.05%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy
PTCT	PTC Therapeutics	$47.02	$48.00	2.08%	Hold

VKTX Forecast FAQ

Is Viking Therapeutics a good buy?

Yes, according to 11 Wall Street analysts, Viking Therapeutics (VKTX) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 10 'Buy' recommendations, accounting for 100.00% of VKTX's total ratings.

What is VKTX's price target?

Viking Therapeutics (VKTX) average price target is $97.8 with a range of $74 to $110, implying a 135.72% from its last price of $41.49. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Viking Therapeutics stock go up soon?

According to Wall Street analysts' prediction for VKTX stock, the company can go up by 135.72% (from the last price of $41.49 to the average price target of $97.8), up by 165.12% based on the highest stock price target, and up by 78.36% based on the lowest stock price target.

Can Viking Therapeutics stock reach $60?

VKTX's average twelve months analyst stock price target of $97.8 supports the claim that Viking Therapeutics can reach $60 in the near future.

What is Viking Therapeutics's current price target trend?

1 Wall Street analyst forecast a $74 price target for Viking Therapeutics (VKTX) this month, up 78.36% from its last price of $41.49. Compared to the last 3 and 12 months, the average price target increased by 136.20% and increased by 159.22%, respectively.

What are Viking Therapeutics's analysts' financial forecasts?

Viking Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-190M (high $-190M, low $-190M), average SG&A $0 (high $0, low $0), and average EPS is $-1.716 (high $-1.716, low $-1.716). VKTX's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-192M (high $-192M, low $-192M), average SG&A $0 (high $0, low $0), and average EPS is $-1.735 (high $-1.735, low $-1.735).